METTL3 and hepatocellular carcinoma: To confirm the role of METTL3 in sorafenib resistance, we systematically analyzed the GSE62813 database for the change of METTL3 expression in HepG‐2 cells and sorafenib‐resistant HepG‐2 cells, and found that METTL3 was significantly down‐regulated in sorafenib‐resistant HCC cells (Fig 1F).